Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 417-425

  Maurice, Andrew ^a   Evans, D Gareth ^a,b   Affen, Jenny ^a   Greenhalgh, Rosemary ^a   Duffy, Stephen W ^c   Howell, Anthony ^a,d  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BRCA1; BRCA2; breast cancer; CBE; mammography

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SURVIVAL RATE; TUMOR VOLUME;

ADULT; BREAST; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PALPATION; RISK FACTORS;

EID: 84861582041     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26394     Document Type: Article

References (29)

1. Cancer Research UK Statistics. Available at: http://info. cancerresearchuk.org/cancerstats/index.htm. Accessed 1st June 2011.
2. Calle EE, Martin LM, Thun MJ, Miracle HL, Heath CW, Jr., Family history, age, and risk of fatal breast cancer. Am J Epidemiol 1990; 131: 961-72.
3. McClain MR, Palomaki GE, Nathanson KL, Haddow JE,: Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005; 7: 28-33.
4. Pharoah PDP, Antoniou AC,., Easton DF, Ponder BAJ,. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-803.
5. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-9.
6. FH01 Collaborative Teams. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 2010; 11: 1127-34.
7. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A, Asselain B,. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. Clin Oncol 2000; 24: 4053-9.
8. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM,. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 2007; 121: 1017-20.
9. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA,. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Eng J Med 2007; 357: 115-23.
10. Loman N, Johannsson O, Benndahl P-O, Dahl N, Einbeigi Z, Gerdes A, Borg A, Olsson H,. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 2000; 36: 1365-73.
11. Lalloo F, Boggis CRM, Evans DGR, Shenton A, Threlfall AG, Howell A,. Screening by mammography women with a family history of breast cancer. Eur J Cancer 1998; 34: 937-40.
12. Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A,. Screening younger women with a family history of breast cancer - does early detection improve outcome? Eur J Cancer. 2006; 42: 1385-90.
13. Brekelmans C, Tilanus-Linthorst M, Seynaeve C, vd Ouweland A, Menke-Pluymers M, Bartels C, Kriege M, van Geel A, Burger C, Eggermont A,. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007; 43: 867-76.
14. Eccles DM, Evans DGR, Mackay J,. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet 2000; 37: 203-9.
15. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. National Institute for Health and Clinical Excellence. Clinical guidelines CG41. Issued: October 2006 updated from original comprehensive guidance CG14 June 2004. Available at: www.nice.org.uk.
16. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A,. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003; 40: 807-14.
17. Amir E, Freedman OC, Seruga B, Evans DG,. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010; 102: 680-91.
18. Baines CJ, Miller AB, Bassett AA,. Physical examination: evaluation of its role as a single screening modality in the Canadian National Breast Screening Study. Cancer 1989; 63: 160-66.
19. Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH, Houssami N, Kearins O, Tappenden N, O'Sullivan E, Duffy SW,. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009; 116: 179-85.
20. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
21. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-25.
22. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL,. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007; 25: 642-7.
23. Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, Hudis C, Offit K, Robson M,. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 2007; 13: 4306-10.
24. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505-10.
25. McDonald S, Saslow D, Alciati MH,. Performance and reporting of clinical breast examination: a review of the literature. CA Cancer J Clin 2004; 54: 345-61.
26. Bancej C, Decker K, Chiarelli AM, Harrison M, Turner D, Brisson J,. Contribution of clincial breast examination to mammographic screening in the early detection of breast cancer. J Med Screen 2003; 10: 16-21.
27. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE, Yasui Y, Daling JR, Potter JD,. Detection method and breast carcinoma histology. Cancer 2002; 95: 470-77.
28. Chiarelli AM, Majpruz V, Brown P, Theriault M, Shumak R, Mai V,. The contribution of clinical breast examination to accuracy of breast screening. J Natl Cancer Inst 2009; 101: 1236-43.
29. Gui GP, Hogben RK, Walsh G, A'Hern R, Eeles R,. The incidence of breast cancer from screening women according to predicted family history risk: does annual clinical examination add to mammography? Eur J Cancer. 2001; 37: 1668-73.